The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Advances clinical research capabilities with leading regulatory grade registries platform
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Subscribe To Our Newsletter & Stay Updated
